The purpose of this exploratory study was to examine the interaction of 5-HTTLPR
and DRD4 exon III polymorphisms with gender in non-treatment seeking
alcohol dependent (AD) individuals while alternately taking ondansetron and sertraline.
Evidence suggests that alcohol dependence may be influenced by a genetic interaction that
may be gender specific with temporal changes making pharmacological treatment with
serotonergic drugs complex. The main trial was a within-subject double-blind
placebo-controlled human laboratory study with 77 non-treatment-seeking AD individuals
randomized (55 completed, 49 complete data) to receive 200mg/day of sertraline or
0.5mg/day of ondansetron for 3-weeks followed by an alcohol self-administration experiment
(ASAE), then placebo for three weeks followed by a second ASAE, then receive the alternate
drug, in a counterbalanced order, for three weeks followed by a third ASAE. Results for
men were not significant. Women with the LL 5-HTTLPR genotype receiving ondansetron and
SS/SL 5-HTTLPR genotypes receiving sertraline (matched), drank significantly fewer drinks
per drinking day (DDD) during the 7-days prior to the first and third ASAEs than women
receiving the mismatched medication (i.e. sertraline to LL and ondansetron to SS/SL). In a
three-way interaction, 5-HTTLPR alleles by DRD4 alleles by medications,
women with the LL genotype who received ondansetron and had DRD4
≥7 exon III repeats drank significantly fewer DDD as did SS/SL women who received
sertraline but conversely had DRD4 <7-repeats in the 7-day period
leading up to the first and third ASAEs. Consistent with these data was a significant
reduction of milliliters consumed ad lib during these same ASAEs. These
exploratory findings add possible support to gender and genetic differences among AD
individuals in response to serotonergic pharmacotherapies. Future trials should be
powerful enough to take into account that endophenotypes and a targeting of serotonergic
interactions may be essential to successfully treat alcohol dependence.